Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 19, 2024 - Issue
Submit an article Journal homepage
80
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Dosing Strategy to Improve Adherence to Roflumilast in Treatment for Chronic Obstructive Lung Disease: A Systemic Review and Meta-Analysis

Jonghoo Lee1 Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2626-7099View further author information
ORCID Icon &
Jae-Uk Song2 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaView further author information
Pages 655-663 | Received 15 Sep 2023, Accepted 26 Jan 2024, Published online: 04 Mar 2024

References

  • Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–1266. doi:10.1056/NEJMra1900500
  • Lopez-Campos JL, Soler-Cataluna JJ, Miravitlles M. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2019 report: future challenges. Arch Bronconeumol. 2020;56(2):65–67. doi:10.1016/j.arbres.2019.06.001
  • Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother. 2006;40(6):1096–1104. doi:10.1345/aph.1E651
  • Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694. doi:10.1016/S0140-6736(09)61255-1
  • Shen LF, Lv XD, Chen WY, Yang Q, Fang ZX, Lu WF. Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ir J Med Sci. 2018;187(3):731–738. doi:10.1007/s11845-018-1738-9
  • The Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report; 2023. Available from: https://goldcopd.org/about-us/. Accessed June 16, 2023.
  • Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016;15(8):1133–1146. doi:10.1080/14740338.2016.1199683
  • Williams D. The role of the pharmacist in optimizing outcomes with roflumilast, a PDE4 Inhibitor for the Treatment of COPD. J Pharm Pract. 2022;35(3):445–454. doi:10.1177/0897190020969286
  • Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–256. doi:10.1016/j.pupt.2010.03.011
  • Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
  • Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
  • Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.1186
  • Hwang H, Shin JY, Park KR, et al. Effect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis. 2015;78(4):321–325. doi:10.4046/trd.2015.78.4.321
  • Park TS, Kang J, Lee JS, Oh YM, Lee SD, Lee SW. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:871–879. doi:10.2147/COPD.S191033
  • Watz H, Bagul N, Rabe KF, et al. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:813–822. doi:10.2147/COPD.S154012
  • Joo H, Han D, Lee JH, Rhee CK. Incidence of adverse effects and discontinuation rate between patients receiving 250 micrograms and 500 micrograms of roflumilast: a comparative study. Tuberc Respir Dis. 2018;81(4):299–304. doi:10.4046/trd.2018.0015
  • Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563–571. doi:10.1016/S0140-6736(05)67100-0
  • Zeng S, Bai H, Zou M. Effects of roflumilast on patients with chronic obstructive pulmonary disease treated with inhaled corticosteroid/long-acting beta2 agonist: a meta-analysis. Comput Math Methods Med. 2022;2022:8101099. doi:10.1155/2022/8101099
  • Munoz-Esquerre M, Diez-Ferrer M, Monton C, et al. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther. 2015;30:16–21. doi:10.1016/j.pupt.2014.10.002
  • Lahu G, Facius A. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther. 2013;51(11):832–836. doi:10.5414/cp201906
  • Kim KH, Kang HS, Kim JS, Yoon HK, Kim SK, Rhee CK. Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:3449–3456. doi:10.2147/COPD.S143967
  • Lee JS, Cheong HS, Kim LH, et al. Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. Korean J Physiol Pharmacol. 2013;17(6):479–484. doi:10.4196/kjpp.2013.17

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.